Pashna N. Munshi

发表

Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B Cell Lymphoma.

F. Awan, A. Goodman, F. Locke, 2022, Transplantation and cellular therapy.

Lower GVHD and relapse risk in PTCy-based Haploidentical vs Matched Sibling Donor RIC Transplant for Hodgkin Lymphoma

M. Aljurf, J. Bolaños-Meade, Y. Nieto, 2019 .

Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation.

R. Feinman, R. Korngold, P. Fields, 2020, Transplantation and cellular therapy.

Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

S. de Vos, D. Maloney, I. Yakoub-Agha, 2021, Blood.

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

G. Salles, D. Maloney, V. Plaks, 2020 .

Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less.

J. Szer, D. Stroncek, J. Liesveld, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

6-thioguanine: a drug with unrealized potential for cancer therapy.

J. Bertino, M. Lubin, P. Munshi, 2014, The oncologist.

Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells (HSC) Used in Salvage Autologous Stem Cell Transplantation: Prolonged Storage of HSCs Sustains Hematological Reconstitution Potential.

D. Siegel, D. Vesole, M. Donato, 2022, Transplantation and cellular therapy.

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.

G. Salles, S. de Vos, D. Maloney, 2021, The Lancet. Oncology.

Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients

K. Dunleavy, K. Makambi, A. Goy, 2022, Blood advances.

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.

Shannon R. McCurdy, M. Perales, R. Soiffer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

P. Riedell, F. Awan, M. Krem, 2021, JAMA oncology.

The acceleration of CAR‐T therapy in non‐Hodgkin lymphoma

C. Ujjani, Pashna N. Munshi, 2018, Hematological oncology.

Planned granulocyte-colony stimulating factor adversely impacts survival after allogeneic hematopoietic cell transplantation performed with Thymoglobulin for myeloid malignancy.

M. Grunwald, O. Ringdén, H. Lazarus, 2021, Transplantation and cellular therapy.

Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24).

G. Salles, D. Maloney, V. Plaks, 2021 .

Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).

G. Salles, D. Maloney, V. Plaks, 2020 .

Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis

Sonali M. Smith, R. Vij, W. Wood, 2019, Blood Cancer Journal.

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma

P. Hari, J. Zaucha, M. Krem, 2020, Cancer.

Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission.

C. Turtle, M. Pasquini, F. Locke, 2021, Blood.

ASTCT, CIBMTR and EBMT Clinical Practice recommendations for transplant and cellular therapies in mantle cell lymphoma.

Michael L. Wang, Sonali M. Smith, J. Friedberg, 2021, Bone Marrow Transplantation.

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Michael L. Wang, Sonali M. Smith, J. Friedberg, 2021, Transplantation and cellular therapy.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in T-cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.

J Wagner, F. Awan, M. Krem, 2022, Transplantation and cellular therapy.

Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

Shannon R. McCurdy, M. Perales, M. Horowitz, 2016 .

Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.

M. Perales, M. Aljurf, Y. Nieto, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma

P. Hari, J. Zaucha, Shaji K. Kumar, 2019, Blood.

Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease.

S. Steinberg, L. Morton, E. Cowen, 2021, Transplantation and cellular therapy.

The Transplant Ecosystem: A New Concept to Improve Access and Outcomes for Older Allogeneic Hematopoietic Cell Patients.

Shannon R. McCurdy, D. Howard, R. Jayani, 2023, Transplantation and cellular therapy.

Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Shaji K. Kumar, M. Aljurf, Y. Nieto, 2023, Blood advances.

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

D. Siegel, M. Atkins, R. Feinman, 2018, Blood.

Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older

P. Hari, Shaji K. Kumar, M. Qazilbash, 2021, Cancer.